DOR BioPharma, Inc. has announced that it has submitted in the Electronic Common Technical Document format a New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") to market ...
DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD PRINCETON, N.J., June 9 -- DOR BioPharma, Inc. (DOR or the Company) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results